Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JT, Torii Ditch Pruritus Candidate Development
June 29, 2018
- Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
- Japan’s 1st Rituxan Biosimilar Boasts 13% Share: Sandoz Country Head
June 28, 2018
- DPP-4/SGLT2 Combo Sujanu Most Heavily Pitched for GPs in May: Anterio
June 28, 2018
- AbbVie Eyes Global Simultaneous Launch for Autoimmune Disease Treatments: Exec
June 28, 2018
- Keytruda’s MSI-H Cancer Indication to Be Reviewed Under Conditional Early Approval System
June 28, 2018
- Chugai Chairman Prods Drug Makers to Innovate, Chides Calls for Relaxed Pricing
June 27, 2018
- FDA Decision on Shionogi’s Single-Dose Drug Expected by Dec. 24
June 27, 2018
- Rohto Takes 15% Stake in Shionogi’s Consumer Healthcare Unit
June 26, 2018
- Lonsurf Cuts Risk of Death by 31% in Metastatic Gastric Cancer
June 26, 2018
- Meiji, Hiroshima Univ. Spinout Hook Up on Cell Therapies for Osteoarthritis
June 26, 2018
- Xofluza Likely to Jolt Japan Flu Market This Winter
June 25, 2018
- J-TEC Enters License Agreement on Low-Cost Manufacturing of CAR-T Cells with 2 Universities
June 25, 2018
- Kowa Sues Towa for Damages Caused by Livalo Generics
June 25, 2018
- Generic Specialist Ohara to Develop Novel Liver Cirrhosis Treatment Licensed from Japanese Startup
June 25, 2018
- Maviret Sweeping Japan Hep C Market, 80% Share Snatched in Just 4 Months?
June 22, 2018
- Nippon Zoki Applies for Approval of 3-Day Fentanyl Patch for Cancer Pain
June 22, 2018
- AbbVie, Eisai Launch Pediatric Formulation of Humira
June 22, 2018
- AstraZeneca Completes Transfer of Migraine Drug Zomig to Sawai
June 21, 2018
- Remicade Biosimilar Gets New Dosage Nod for Psoriasis, Crohn’s Disease: Nichi-Iko/Ayumi
June 21, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…